Send me real-time posts from this site at my email

Pfizer's (PFE) Prevnar 20 Plus COVID Vaccine Study Succeeds

Pfizer PFE announced positive top-line data from a phase III study evaluating the co-administration of its newly approved 20-valent pneumococcal conjugate vaccine, Prevnar-20 with it and partner BioNTech’s BNTX mRNA-based COVID-19 vaccine at the same time in adults 65 years of age or older.

The study also evaluated the safety and immunogenicity of Prevnar 20 and COVID vaccine each given with a placebo. Data from the study demonstrated similar responses elicited by Prevnar 20 for all 20 serotypes whether given with a dose of COVID-19 vaccine or with placebo. The responses generated by a booster shot of the COVID-19 vaccine were also similar when given with Prevnar 20 or a placebo 

The safety profile for the co-administration of Prevnar 20/COVID-19 vaccine booster dose was similar to that observed with the booster dose.

The data clearly shows that the COVID-19 and pneumococcal vaccines can be given at the same time, thereby reducing the number of patient visits to the doctor. The study evaluating the coadministration of Prevnar 20 along with a booster dose of the COVID-19 vaccine was initiated in May last year.

Pfizer’s stock has risen 60.2% in the past year compared with an increase of 21.4% for the industry.

Image Source: Zacks Investment Research

Prevnar-20 was approved in the United States in June 2021 while it is under review in the EU.

Pfizer and BioNTech’s COVID-19 vaccine was developed in record time and is now approved for emergency/temporary use in several countries worldwide and fully approved in the United States. Pfizer and BioNTech’s vaccine was approved for younger patients (5-17 years) while a booster vaccine dose was also approved in the United States in 2021.

Pfizer and BioNTech’s COVID-19 vaccine has become a key contributor to the top line. In the first nine months of 2021, the vaccine contributed $24.3 billion to Pfizer’s global sales. The pharma giant expects 2021 Comirnaty revenues to be $36.0 billion. The fourth-quarter and full-year 2021 results are expected to be announced on Feb 8.

Pfizer sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Some other top-ranked stock large drug/biotech stocks are AbbVie ABBV and Regeneron REGN, both with a Zacks Rank of 2 (Buy).

AbbVie’s stock has risen 27.3% in the past year. Estimates for AbbVie’s 2022 earnings have gone up from $13.99 to $14.09 over the past 60 days.

AbbVie’s earnings performance has been strong with the company exceeding earnings expectations in each of the last four quarters. AbbVie has a four-quarter earnings surprise of 3.02%, on average.

Regeneron’s 2022 earnings per share estimates have risen from $46.98 to $48.06 over the past 60 days. REGN’s stock is up 21.9% year over year.

Regeneron’s earnings performance has been strong with the company exceeding earnings expectations in each of the last four quarters. Regeneron has a four-quarter earnings surprise of 28.93%, on average.


Bitcoin, Like the Internet Itself, Could Change Everything

Blockchain and cryptocurrency has sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.

Zacks’ has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly. 

See 3 crypto-related stocks now >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Regeneron Pharmaceuticals, Inc. (REGN): Free Stock Analysis Report
 
Pfizer Inc. (PFE): Free Stock Analysis Report
 
AbbVie Inc. (ABBV): Free Stock Analysis Report
 
BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue